Every 10-Q that NUTRA PHARMA CORP (NPHC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NPHC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NPHC filings page.
NUTRA PHARMA CORP (NPHC) reports very weak financials for the quarter and six months ended June 30, 2026. The company generated modest product revenue, with net sales of $34,463 and related-party sales of $23,459 in the quarter, and continues to post negative gross margins after operating expenses. For the six months, net sales were $61,709 and related-party sales $44,427, while the net loss widened sharply to $4,408,447 from $1,035,346 a year earlier, driven largely by a $3,526,007 loss from changes in the fair value of convertible notes and derivatives.
The balance sheet is highly stressed: total assets were only $622,863 versus total liabilities of $21,831,616, resulting in a stockholders’ deficit of $21,208,753. Current liabilities of $21,696,808 include $12,573,897 of debt, most of which is in default, with $4,495,723 of convertible notes carried at fair value and $2,037,134 of derivative liabilities. Cash was $0 at June 30, 2026, and operating activities used $579,014 of cash in the first half, funded mainly by new high-cost convertible borrowings and receivables financings.
Management states there is substantial doubt about NPHC’s ability to continue as a going concern, citing recurring losses, a working capital deficit of $21,233,689, extensive indebtedness in default, and reliance on debt and equity funding that has not been sufficient to execute its business plan. The common stock trades on the OTC Expert Market, which the company notes limits its ability to raise capital. A very large overhang of deeply discounted, defaulted convertible notes and derivative features could lead to significant dilution if conversions occur.
Nutra Pharma Corp. reported a net loss of $459,675 for the three months ended March 31, 2026, narrower than the $1,404,923 loss a year earlier. Net sales were $27,246 and net sales to a related party added $20,968, both down from $73,974 and $36,420 in the prior-year period.
Operating expenses were $398,224, producing a loss from operations of $379,249. A $140,500 gain on settlement of debt partly offset interest and derivative fair-value charges, reducing total other expenses. Cash increased to $21,844 as of March 31, 2026, but operations used $327,791 of cash in the quarter.
The balance sheet remains highly leveraged. Total assets were $616,518 versus total liabilities of $17,878,499, creating a stockholders’ deficit of $17,261,981. The company discloses a working capital deficit of $17,243,345, significant indebtedness in default and extensive convertible notes, many at deep discounts to market.
Management states there is substantial doubt about Nutra Pharma’s ability to continue as a going concern without new financing and improved profitability. As of May 29, 2026, there were 7,159,727,214 common shares and 12,000,000 Series B preferred shares outstanding. The company has also accrued a legal settlement of $680,235 arising from a final judgment in an SEC enforcement action.
Nutra Pharma Corp. reported modest revenue but continued heavy losses in its quarter ended September 30, 2025. Net sales for the nine months were $228,748, up from $164,436 a year earlier, yet the company posted a nine‑month net loss of $1,558,866.
Nutra Pharma ended the period with cash of only $3,603 and total assets of $709,853, against total liabilities of $17,060,633. Stockholders’ deficit widened to $16,350,780, and management disclosed a working capital deficit of $16,377,977 and substantial doubt about the company’s ability to continue as a going concern.
The company relies heavily on debt and equity funding, including numerous convertible notes, many of which are in default or under negotiation for settlement. As of April 6, 2026, there were 7,159,727,214 common shares and 12,000,000 Series B preferred shares outstanding, reflecting significant leverage and dilution risk.
Nutra Pharma Corp reports Q2 2025 results showing net income of $369,577, reversing a prior-year quarterly loss, largely due to a $704,622 gain from changes in the fair value of convertible notes and derivatives and a $53,526 gain on debt settlements.
Core operations remain weak. For the three months ended June 30, 2025, net sales were $84,532 plus $37,611 to a related party, generating gross profit of only $75,628 against selling, general and administrative expenses of $366,157, resulting in a loss from operations of $290,529. For the six-month period, the company recorded a net loss of $1,035,346.
The balance sheet is highly leveraged, with total assets of $859,068 versus total liabilities of $16,692,328, including $9,345,780 of current debt and $924,516 of derivative liabilities. Stockholders’ deficit was $15,833,260, and the accumulated deficit reached $77,266,483.
Liquidity is strained: cash was only $79,069 at June 30, 2025, after using $693,376 in operating cash during the first half, funded mainly by $810,056 of new convertible notes and officer loans. Management discloses a working capital deficit of $15,888,753, numerous defaulted debts, dependence on external financing, and explicitly states there is substantial doubt about the company’s ability to continue as a going concern, exacerbated by its common stock trading on the OTC Market Group’s Expert Market, which restricts capital-raising options.
Nutra Pharma Corp. reported higher net sales but a much larger loss for the quarter ended March 31, 2025. Net sales rose to $73,974 from $37,732, plus $36,420 of related-party sales, yet the company posted a net loss of $1,404,923 versus $426,934 a year earlier. The deeper loss was driven by operating expenses of $418,150, interest costs, and a $1,007,309 loss from changes in the fair value of convertible notes and derivatives.
Nutra Pharma ended the quarter with only $13,843 of cash, total assets of $775,179, and total liabilities of $16,988,016, resulting in a stockholders’ deficit of $16,212,837. Management discloses substantial doubt about the company’s ability to continue as a going concern, citing an accumulated deficit of $77,636,060, a working capital deficit of $16,296,563, heavy debt—much of it in default, including $9,057,034 of notes—and tight access to capital with its stock on the OTC Expert Market. The company has also accrued $680,235 for an SEC legal judgment and relies on new convertible debt financings to fund operations while it seeks to grow sales of its pain relief products.
Nutra Pharma Corp. reports another quarterly loss and highlights serious financial strain in its Q3 2024 report. For the nine months ended September 30, 2024, net sales were $164,436 with additional related-party sales of $106,184, while the company recorded a net loss of $1,054,756, similar to the prior year’s loss. Gross profit fell compared with 2023 as operating expenses continued to exceed revenue.
The balance sheet shows total assets of $558,838 against total liabilities of $15,378,402, resulting in a stockholders’ deficit of $14,819,564. The company discloses that it had no cash at period-end, a working capital deficit of $14,902,502, and significant debt, much of it in default or convertible. Management states there is substantial doubt about its ability to continue as a going concern and notes that common stock trades on the OTC Expert Market, which limits capital-raising options.